نتائج البحث - Jeremy Hoog

تنقيح النتائج
  1. 1
    Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer

    Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer حسب Sandeep Rajput, Nimmish Khera, Zhanfang Guo, Jeremy Hoog, Shunqiang Li, X. Cynthia

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers

    Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers حسب Meenakshi Anurag, Nindo Punturi, Jeremy Hoog, Matthew N. Bainbridge, Matthew J. Ellis, Svasti Haricharan

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Vav1/2/3-null Mice Define an Essential Role for Vav Family Proteins in Lymphocyte Development and Activation but a Differential Requirement in MAPK Signaling in T and B Cells

    Vav1/2/3-null Mice Define an Essential Role for Vav Family Proteins in Lymphocyte Development and Activation but a Differential Requirement in MAPK Signaling in T and B Cells حسب Keiko Fujikawa, Ana V. Miletic, Frederick W. Alt, Roberta Faccio, Tracie Brown, Jeremy Hoog, Jessica Fredericks, Shinzo Nishi, Shirly Mildiner, Sheri L. Moores, Joan S. Brugge, Fred S. Rosen, Wojciech Swat

    منشور في 2003
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

    A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer حسب X. Cynthia, César Sánchez, Feng Gao, Robert J. Crowder, Michael Naughton, Timothy Pluard, Allison Creekmore, Zhanfang Guo, Jeremy Hoog, A. Craig Lockhart, Austin Doyle, Charles Erlichman, Matthew J. Ellis

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

    Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models حسب X. Cynthia, Shirong Cai, Shunqiang Li, Christine E. Ryan, Zhanfang Guo, W. Timothy Schaiff, Lin Li, Jeremy Hoog, Reece Goiffon, Aleix Prat, Rebecca Aft, Matthew J. Ellis, Helen Piwnica‐Worms

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance)

    Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance) حسب Meenakshi Anurag, Mayanne M. T. Zhu, Chen Huang, Suhas Vasaikar, Junkai Wang, Jeremy Hoog, Samantha Burugu, Dongxia Gao, Vera J. Suman, Xiang H.-F. Zhang, Bing Zhang, Torsten O. Nielsen, Matthew J. Ellis

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal Women

    Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal Women حسب Anita K. Dunbier, H Anderson, Zara Ghazoui, Elizabeth Folkerd, Roger A’Hern, Robert J. Crowder, Jeremy Hoog, Ian E. Smith, Peter Osin, Ashutosh Nerurkar, Joel S. Parker, Charles M. Perou, Matthew J. Ellis, Mitch Dowsett

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer

    Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer حسب Rodrigo Gonçalves, Katherine DeSchryver, X. Cynthia, Tao Yu, Jeremy Hoog, Maggie C.U. Cheang, Erika C. Crouch, Neha Dahiya, Souzan Sanati, Michael Barnes, Luı́s Otávio Sarian, John A. Olson, D. Craig Allred, Matthew J. Ellis

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

    Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib حسب Nusayba A. Bagegni, Shana Thomas, Ning Liu, Jingqin Luo, Jeremy Hoog, Donald W. Northfelt, Matthew P. Goetz, Andres Forero, Mattias Bergqvist, Jakob Karén, Magnus Neumüller, Edward M. Suh, Zhanfang Guo, Kiran Vij, Souzan Sanati, Matthew J. Ellis, X. Cynthia

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    ESR1 gene amplification in breast cancer: a common phenomenon?

    ESR1 gene amplification in breast cancer: a common phenomenon? حسب Lindsay Brown, Jeremy Hoog, Suet‐Feung Chin, Yu Tao, Abd Alnaser Zayed, Koei Chin, Andrew E. Teschendorff, John F. Quackenbush, John C. Marioni, Samuel Leung, Charles M. Perou, Torsten O Neilsen, Matthew J. Ellis, Joe W. Gray, Philip S. Bernard, David G. Huntsman, Carlos Caldas

    منشور في 2008
    احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

    Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer حسب Matthew J. Ellis, Lin Li, Robert J. Crowder, Tao Yu, Jeremy Hoog, Jacqueline Snider, Sherri R. Davies, Katherine DeSchryver, Dean B. Evans, Jutta Steinseifer, Raj Bandaru, Weihua Liu, Humphrey Gardner, Semiglazov Vf, Mark A. Watson, Kelly K. Hunt, John A. Olson, José Baselga

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    <i>PIK3CA</i>and<i>PIK3CB</i>Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer

    <i>PIK3CA</i>and<i>PIK3CB</i>Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer حسب Robert J. Crowder, Chanpheng Phommaly, Tao Yu, Jeremy Hoog, Jingqin Luo, Charles M. Perou, Joel S. Parker, Melinda A. Miller, David G. Huntsman, Lin Li, Jacqueline Snider, Sherri R. Davies, John A. Olson, Mark A. Watson, Anthony J. Saporita, Jason D. Weber, Matthew J. Ellis

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer

    Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer حسب Svasti Haricharan, Nindo Punturi, Purba Singh, Kimberly Holloway, Meenakshi Anurag, Jacob Schmelz, Cheryl Schmidt, Jonathan T. Lei, Vera J. Suman, Kelly K. Hunt, John A. Olson, Jeremy Hoog, Shunqiang Li, Shixia Huang, Dean P. Edwards, Shyam M. Kavuri, Matthew N. Bainbridge, X. Cynthia, Matthew J. Ellis

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

    A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer حسب X. Cynthia, Jingqin Luo, Michael Naughton, Foluso O. Ademuyiwa, Rama Suresh, Malachi Griffith, Obi L. Griffith, Zachary L. Skidmore, Nicholas C. Spies, Avinash Ramu, Lee Trani, Timothy Pluard, Gayathri Nagaraj, Shana Thomas, Zhanfang Guo, Jeremy Hoog, Jing Han, Elaine R. Mardis, Craig Lockhart, Matthew J. Ellis

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

    Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical... حسب Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Lin Li, Jacqueline Snider, Aleix Prat, Joel S. Parker, Jingqin Luo, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary Unzeitig, Julie Margenthaler, Gildy V. Babiera, P. Kelly Marcom, Joseph M. Guenther, Mark A. Watson, Marilyn Leitch, Kelly K. Hunt, John A. Olson

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers

    Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers حسب Christopher A. Miller, Yevgeniy Gindin, Charles Lu, Obi L. Griffith, Malachi Griffith, Dong Shen, Jeremy Hoog, Tiandao Li, David E. Larson, Mark A. Watson, Sherri R. Davies, Kelly K. Hunt, Vera J. Suman, Jacqueline Snider, Thomas Walsh, Graham A. Colditz, Katherine DeSchryver, Richard K. Wilson, Elaine R. Mardis, Matthew J. Ellis

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    CDK4/6 inhibition triggers anti-tumour immunity

    CDK4/6 inhibition triggers anti-tumour immunity حسب Shom Goel, Molly J. DeCristo, April C. Watt, Haley BrinJones, Jaclyn Sceneay, Ben B. Li, Naveed Khan, Jessalyn M. Ubellacker, Shaozhen Xie, Otto Metzger, Jeremy Hoog, Matthew J. Ellis, X. Cynthia, Susanne Ramm, Ian E. Krop, Eric P. Winer, Thomas M. Roberts, Hye Jung Kim, Sandra S. McAllister, Jean J. Zhao

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity

    Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity حسب Xiuli Zhang, Samuel Kim, Jasreet Hundal, John M. Herndon, Shunqiang Li, Allegra A. Petti, Savas D. Soysal, Lijin Li, Michael D. McLellan, Jeremy Hoog, Tina Primeau, Nancy B. Myers, Tammi L. Vickery, Mark Sturmoski, Ian S. Hagemann, Chris Miller, Matthew J. Ellis, Elaine R. Mardis, Ted H. Hansen, Timothy P. Fleming, S. Peter Goedegebuure, William E. Gillanders

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination

    Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combin... حسب X. Cynthia, Vera J. Suman, Souzan Sanati, Kiran Vij, Meenakshi Anurag, A. Marilyn Leitch, Gary Unzeitig, Jeremy Hoog, Aranzazu Fernández-Martínez, Cheng Fan, Richard A. Gibbs, Mark A. Watson, Travis Dockter, Olwen Hahn, Joseph M. Guenther, Abigail S. Caudle, Erika C. Crouch, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J. Hieken, Yang Wang, Mothaffar F. Rimawi, Anna Weiss, Eric P. Winer, Kelly K. Hunt, Charles M. Perou, Matthew J. Ellis, Ann H. Partridge, Lisa A. Carey

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

    Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surg... حسب Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Rodrigo Gonçalves, Souzan Sanati, Chad J. Creighton, Katherine DeSchryver, Erika C. Crouch, Amy Brink, Mark A. Watson, Jingqin Luo, Tao Yu, Michael Barnes, Mitch Dowsett, G. Thomas Budd, Eric P. Winer, Paula Silverman, Laura J. Esserman, Lisa A. Carey, X. Cynthia, Gary Unzeitig, Timothy Pluard, Pat W. Whitworth, Gildy V. Babiera, J. Michael Guenther, Zoneddy Dayao, David M. Ota, Marilyn Leitch, John A. Olson, D. Craig Allred, Kelly K. Hunt

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: